Global Ocular Pain Market
Taille du marché en milliards USD
TCAC :
% 
USD
1.12 Billion
USD
2.02 Billion
2024
2032
 Période de prévision |
2025 –2032 |
 Taille du marché (année de référence) |
USD 1.12 Billion |
 Taille du marché (année de prévision) |
USD 2.02 Billion |
 TCAC |
% |
| Principaux acteurs du marché |
|
Segmentation du marché mondial de la douleur oculaire, par type de maladie (douleur oculaire associée à des maladies oculaires et douleur oculaire sans maladies oculaires primaires), type (diagnostic et traitement), application (conjonctivite, abrasion cornéenne, blépharite, orgelet, iritis, sinusite, migraines, glaucome et autres), voie d'administration (topique, périoculaire, intraoculaire, orale), type de médicament (sur ordonnance et en vente libre), type de population (adultes et personnes âgées), utilisateur final (hôpitaux, cliniques spécialisées, établissements de soins à domicile, centres d'ophtalmologie, centres de chirurgie ambulatoire et autres), canal de distribution (achat direct, pharmacie hospitalière, pharmacie de détail, pharmacie en ligne et autres) - Tendances et prévisions du secteur jusqu'en 2032
Taille du marché de la douleur oculaire
- La taille du marché mondial de la douleur oculaire était évaluée à 1,12 milliard USD en 2024 et devrait atteindre 2,02 milliards USD d'ici 2032 , à un TCAC de 7,8 % au cours de la période de prévision.
- La croissance du marché est largement alimentée par un mode de vie de plus en plus insalubre et sédentaire
- De plus, la douleur oculaire sensibilise davantage le public aux maladies oculaires. Ces facteurs convergents accélèrent l'adoption de solutions contre la douleur oculaire, stimulant ainsi considérablement la croissance du secteur.
Analyse du marché de la douleur oculaire
- Les traitements de la douleur oculaire, englobant des approches pharmaceutiques et non pharmaceutiques, gagnent du terrain en raison de leur efficacité dans la gestion de l'inconfort oculaire causé par les traumatismes, les infections, l'inflammation et la récupération post-chirurgicale.
- La prévalence croissante des troubles oculaires, associée à l'augmentation du temps passé devant un écran, au vieillissement de la population et à une sensibilisation accrue à la santé oculaire, stimule la demande de solutions de gestion de la douleur oculaire à l'échelle mondiale.
- L'Amérique du Nord devrait dominer le marché de la douleur oculaire avec la plus grande part de revenus de 45,05 % en 2025, soutenue par une population gériatrique croissante, un accès élargi aux soins ophtalmiques et une augmentation des dépenses de santé dans des économies clés telles que les États-Unis et le Canada.
- L'Amérique du Nord devrait être la région connaissant la croissance la plus rapide sur le marché de la douleur oculaire au cours de la période de prévision, alimentée par l'augmentation des cas de syndrome de l'œil sec, la pollution urbaine, l'utilisation d'appareils numériques et la présence croissante de grandes sociétés pharmaceutiques.
- Le segment des douleurs oculaires liées aux maladies oculaires devrait dominer le marché des douleurs oculaires avec une part de marché de 73,17 % en 2025, grâce à leur efficacité à réduire l'inflammation et la douleur postopératoire, leur disponibilité facile et leur adoption généralisée dans la pratique clinique.
Portée du rapport et segmentation du marché de la douleur oculaire
|
Attributs |
Informations clés sur le marché de la douleur oculaire |
|
Segments couverts |
|
|
Pays couverts |
Asie-Pacifique
Amérique du Nord
Europe
Amérique du Sud
Moyen-Orient et Afrique
|
|
Principaux acteurs du marché |
|
|
Opportunités de marché |
|
|
Ensembles d'informations de données à valeur ajoutée |
Outre les informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse des importations et des exportations, un aperçu de la capacité de production, une analyse de la consommation de production, une analyse des tendances des prix, un scénario de changement climatique, une analyse de la chaîne d'approvisionnement, une analyse de la chaîne de valeur, un aperçu des matières premières/consommables, des critères de sélection des fournisseurs, une analyse PESTLE, une analyse Porter et un cadre réglementaire. |
Tendances du marché de la douleur oculaire
Augmentation des cas de migraine oculaire
- L'un des principaux moteurs du marché mondial de la douleur oculaire est la prévalence croissante de la migraine oculaire, une affection neurologique pouvant entraîner une perte de vision temporaire et de fortes douleurs oculaires, en particulier chez les jeunes adultes. Ce fardeau croissant souligne la nécessité de traitements multidisciplinaires efficaces ciblant les causes nerveuses et vasculaires de l'inconfort oculaire.
- Par exemple, en juin 2025, selon API Care Online, une revue narrative a analysé la physiopathologie multifactorielle de la douleur oculaire liée à la migraine, soulignant l'interaction des voies neuronales, vasculaires et sensorielles. L'étude préconisait un diagnostic plus précoce et des approches thérapeutiques collaboratives pour traiter ces manifestations souvent sous-diagnostiquées.
- Le même mois, Mivision a publié les résultats d'une étude croisée randomisée démontrant que la lubrification oculaire chez les patients souffrant à la fois de migraine et de sécheresse oculaire réduisait significativement la sévérité de la migraine. Ces résultats suggèrent que la prise en charge des symptômes de sécheresse oculaire peut contribuer à soulager la douleur oculaire induite par la migraine, soulignant ainsi le chevauchement de ces pathologies.
- Bien que les migraines oculaires soient souvent aiguës et transitoires, elles peuvent aussi devenir persistantes, entraînant des épisodes récurrents de douleurs oculaires et de troubles visuels. La fréquence croissante de ces cas contribue significativement à la demande mondiale croissante de solutions pour la prise en charge de la douleur oculaire.
- L’augmentation des cas de migraine oculaire, combinée à une reconnaissance clinique croissante et à de nouvelles interventions thérapeutiques, sont des facteurs essentiels propulsant l’expansion du marché mondial de la douleur oculaire, en particulier dans les contextes de soins intégrés neurologique-ophtalmologique.
Dynamique du marché de la douleur oculaire
Conducteur
Sensibilisation accrue du public aux maladies oculaires
- La sensibilisation croissante aux maladies oculaires et à leurs premiers symptômes, comme la douleur oculaire, est un moteur majeur du développement du marché mondial de la douleur oculaire. Les efforts de sensibilisation et les campagnes de santé publique encouragent les individus à rechercher un diagnostic et une intervention rapides, notamment dans les régions en développement.
- Par exemple, en janvier 2023, une étude publiée dans le MDPI sur la sensibilisation aux maladies oculaires courantes en Pologne a révélé qu'une part importante de la population connaissait des affections telles que la cataracte et le glaucome. Bien que la sensibilisation puisse encore s'améliorer, l'étude a souligné que ces connaissances de base peuvent être efficacement exploitées par des initiatives de santé publique pour promouvoir une prise en charge précoce des symptômes tels que la douleur oculaire.
- De plus, en mars 2025, la LVPEI a organisé une marche de sensibilisation au glaucome dans l'Odisha, en Inde, réunissant près de 200 participants, attirant ainsi l'attention sur cette maladie qui touche plus de 80 millions de personnes dans le monde. L'événement comprenait des séances interactives visant à informer les participants sur la douleur oculaire comme symptôme précoce, les facteurs de risque et les traitements disponibles.
- La sensibilisation croissante, portée par les programmes gouvernementaux, les efforts institutionnels et l'engagement communautaire, améliore progressivement les perspectives de détection et de traitement précoces des affections oculaires. Cette évolution contribue significativement à la croissance du marché mondial de la douleur oculaire, car de plus en plus de patients consultent un professionnel de santé à un stade précoce de la maladie.
Retenue/Défi
Coût élevé des traitements et des médicaments oculaires
- Le coût élevé des traitements et des médicaments contre la douleur oculaire constitue un obstacle majeur à l'expansion du marché. Les thérapies innovantes et les gouttes ophtalmiques sur ordonnance, notamment pour les maladies chroniques, sont souvent inabordables pour de nombreux patients, ce qui limite l'accès et l'observance des soins.
- Par exemple, en novembre 2024, selon BMC Ophthalmology, le coût élevé des médicaments a été identifié comme un facteur majeur de non-observance thérapeutique chez les patients atteints de maladies oculaires chroniques comme le glaucome. Une étude menée en milieu rural au Ghana a souligné comment les obstacles socioéconomiques, notamment l'accessibilité financière et l'accès, réduisent l'efficacité et la continuité des traitements.
- De plus, bien que les thérapies de stimulation avancées pour le traitement de la douleur oculaire affichent des taux de réussite allant jusqu'à 95 %, leur coût élevé les met hors de portée de la plupart des patients à revenu moyen dans les pays développés et en développement, ce qui réduit leur adoption généralisée.
- Si les progrès technologiques et les réformes des soins de santé peuvent contribuer à réduire les coûts des traitements au fil du temps, le prix élevé actuel des traitements et médicaments contre la douleur oculaire demeure un frein majeur, notamment sur les marchés sensibles aux coûts. Améliorer l'accessibilité financière par le biais de la couverture d'assurance, de la réglementation des prix et des alternatives génériques est crucial pour garantir une pénétration plus large du marché et de meilleurs résultats pour les patients.
Portée du marché de la douleur oculaire
Le marché est segmenté en fonction du type de maladie, du type, de l'application, de la voie d'administration, du type de médicament, du type de population, de l'utilisateur final et du canal de distribution.
- Par type de maladie
En fonction du type de pathologie, le marché de la douleur oculaire est segmenté en douleur oculaire associée à des pathologies oculaires et douleur oculaire sans pathologies oculaires. En 2025, le segment de la douleur oculaire associée à des pathologies oculaires dominera le marché avec une part de marché de 73,17 %, stimulé par la prévalence mondiale croissante de pathologies telles que le glaucome, la cataracte, le syndrome de l'œil sec et l'uvéite. Ce segment bénéficie d'une sensibilisation accrue, de taux de diagnostic améliorés et de la disponibilité croissante de thérapies ciblées, notamment les collyres stéroïdiens, les anti-inflammatoires et les traitements par stimulation. L'augmentation du nombre d'interventions chirurgicales et la nécessité d'une prise en charge efficace de la douleur postopératoire stimulent la demande dans cette catégorie.
Le segment des douleurs oculaires associées aux maladies oculaires devrait connaître la croissance la plus rapide, soit 7,5 % entre 2025 et 2032, alimenté par l'incidence croissante des troubles oculaires liés à l'âge et la croissance de la population gériatrique mondiale. Le développement de nouveaux médicaments ophtalmiques, associé aux progrès de la détection précoce des maladies, soutient une croissance soutenue du marché. Alors que de plus en plus de patients prennent en charge les affections oculaires douloureuses de manière proactive, la demande de traitements spécialisés dans ce segment continue d'augmenter.
- Par type
Selon le type de douleur, le marché de la douleur oculaire est segmenté en deux segments : le diagnostic et le traitement. En 2025, le diagnostic domine le marché de la douleur oculaire, soutenu par l'utilisation croissante d'outils diagnostiques avancés tels que les examens à la lampe à fente, la tonométrie, la tomographie par cohérence optique (OCT) et les évaluations neurologiques. Un diagnostic précoce et précis des causes sous-jacentes, telles que le glaucome, les migraines ou les infections, est essentiel pour prescrire des stratégies de prise en charge de la douleur adaptées. Le développement des infrastructures de soins oculaires et la sensibilisation croissante renforcent l'adoption du diagnostic dans les marchés développés et en développement.
Le segment du diagnostic affiche le TCAC le plus élevé entre 2025 et 2032, porté par la demande croissante de solutions efficaces pour soulager la douleur oculaire, notamment les collyres stéroïdiens, les AINS, les larmes artificielles et les nouvelles thérapies de stimulation. Les professionnels de santé privilégient largement ces options thérapeutiques pour la prise en charge de la douleur oculaire associée à la convalescence post-opératoire, au glaucome, aux migraines et aux affections oculaires inflammatoires. La disponibilité croissante de formulations médicamenteuses et de techniques thérapeutiques avancées confère à ce segment une position dominante, tant en milieu hospitalier qu'en commerce de détail.
- Par application
En fonction des applications, le marché de la douleur oculaire est segmenté en conjonctivite, abrasion cornéenne, blépharite, orgelet, iritis, sinusite, migraines, glaucome, etc. En 2025, le segment de la conjonctivite représentait une part importante du chiffre d'affaires du marché, stimulée par la forte incidence mondiale de la conjonctivite, tant virale que bactérienne, qui entraîne fréquemment inflammation, rougeurs et douleurs oculaires. Communément appelée « conjonctivite », la conjonctivite touche des personnes de tous âges et se propage facilement en milieu communautaire, ce qui accroît la demande de collyres analgésiques et d'anti-inflammatoires.
Le segment du glaucome devrait enregistrer une forte croissance de 9,3 % entre 2025 et 2032, portée par la prévalence croissante des cas de glaucome à l'échelle mondiale et par l'augmentation du risque chez les populations vieillissantes. La prise de conscience croissante de l'importance d'un diagnostic précoce, combinée aux progrès des techniques chirurgicales et des systèmes d'administration de médicaments, favorise l'expansion du marché. De plus, la disponibilité d'options thérapeutiques innovantes et l'amélioration de l'accès aux soins ophtalmologiques accélèrent encore la demande de solutions pour la prise en charge du glaucome.
- Par voie d'administration
Selon la voie d'administration, le marché de la douleur oculaire est segmenté en médicaments topiques, périoculaires, intraoculaires, oraux et autres. Le segment topique représentait la plus grande part de chiffre d'affaires du marché en 2025, grâce à sa facilité d'application, sa rapidité d'action et sa large disponibilité. Les formulations topiques, telles que les gouttes, les gels et les pommades ophtalmiques, sont couramment prescrites pour la prise en charge de la douleur oculaire causée par des affections telles que la conjonctivite, les abrasions cornéennes, la sécheresse oculaire et l'inflammation post-opératoire. Leur caractère non invasif et leur capacité à procurer un soulagement localisé en font un choix privilégié tant par les professionnels de santé que par les patients.
Le segment des traitements topiques devrait connaître la croissance la plus rapide, soit 7,9 % entre 2025 et 2032, grâce à la préférence croissante des patients pour des options thérapeutiques non invasives et faciles à utiliser. La prise de conscience croissante des avantages des formulations topiques, notamment l'administration ciblée de médicaments et la réduction des effets secondaires systémiques, favorise leur adoption. De plus, les innovations continues en matière de gels, gouttes et onguents ophtalmiques, ainsi que l'augmentation de la population gériatrique sujette à l'inconfort oculaire, devraient soutenir une croissance soutenue du marché dans ce segment.
- Par type de médicament
Selon le type de médicament, le marché de la douleur oculaire est segmenté entre médicaments sur ordonnance et médicaments en vente libre. Le segment des médicaments sur ordonnance représentait la plus grande part de chiffre d'affaires en 2025, en raison de la prévalence croissante des affections oculaires chroniques et graves nécessitant une surveillance médicale spécialisée. Les traitements sur ordonnance, tels que les corticostéroïdes, les anti-inflammatoires non stéroïdiens (AINS) et les formulations ophtalmiques avancées, sont largement utilisés pour la prise en charge de la douleur oculaire associée à la convalescence post-opératoire, au glaucome, à l'uvéite et à d'autres troubles visuels. Le besoin de conseils médicaux et l'efficacité accrue des traitements sur ordonnance en font une option de confiance pour les patients et les professionnels de santé.
Le segment des médicaments sur ordonnance devrait connaître la croissance la plus rapide, soit 8,0 % entre 2025 et 2032, grâce à l'augmentation du nombre de diagnostics de maladies oculaires complexes et à la croissance de la population âgée nécessitant des soins oculaires de longue durée. L'accès accru aux ophtalmologistes, conjugué au développement continu de nouveaux médicaments sur ordonnance présentant des profils de sécurité et d'efficacité améliorés, stimule la demande. De plus, l'élargissement de la couverture santé et la volonté des patients d'opter pour des traitements sur ordonnance devraient soutenir une croissance soutenue du marché dans ce segment.
- Par type de population
En fonction du type de population, le marché des douleurs oculaires est segmenté entre adultes et personnes âgées. Le segment des adultes représentait la plus grande part de chiffre d'affaires en 2025, en raison de l'incidence croissante des douleurs oculaires liées à la fatigue oculaire numérique, aux migraines, aux allergies et aux blessures mineures. L'augmentation du temps passé devant les écrans, l'exposition aux polluants environnementaux et le stress lié au mode de vie ont rendu les adultes plus sensibles à l'inconfort oculaire, alimentant la demande de solutions analgésiques, sur ordonnance et en vente libre.
Le segment des douleurs oculaires chez l'adulte devrait enregistrer une forte croissance de 8,1 % entre 2025 et 2032, portée par l'augmentation des cas de déficience visuelle, de fatigue oculaire numérique et de troubles oculaires liés au mode de vie. La sensibilisation croissante à la santé oculaire, associée à l'adoption croissante de thérapies ophtalmologiques avancées, stimule la demande de traitement chez les adultes. De plus, la disponibilité de solutions ciblées pour la prise en charge de la douleur et l'élargissement de l'accès aux soins spécialisés devraient accélérer la croissance du marché dans ce segment.
- Par utilisateur final
En fonction de l'utilisateur final, le marché de la douleur oculaire est segmenté en hôpitaux, cliniques spécialisées, services de soins à domicile, centres de traitement de la douleur oculaire, centres de chirurgie ambulatoire, etc. En 2025, le segment hospitalier représentait la plus grande part de chiffre d'affaires du marché, grâce au volume élevé d'admissions de patients pour chirurgie oculaire, traumatologie et affections oculaires aiguës nécessitant une prise en charge immédiate de la douleur. Les hôpitaux sont les principaux centres d'administration de traitements avancés, notamment les injections périoculaires, les médicaments sur ordonnance et les soins postopératoires, ce qui en fait un pôle clé pour la prise en charge des douleurs oculaires modérées à sévères.
Le segment hospitalier devrait connaître la croissance la plus rapide, soit 9,0 % entre 2025 et 2032, grâce à l'augmentation du nombre de patients recherchant des soins ophtalmologiques de pointe et à la prévalence croissante des troubles oculaires. L'amélioration continue des infrastructures hospitalières, la disponibilité d'ophtalmologistes spécialisés et l'adoption de technologies diagnostiques et chirurgicales de pointe soutiennent l'expansion du marché. Alors que de plus en plus de patients privilégient les hôpitaux pour un traitement complet des douleurs oculaires et des affections associées, la demande de soins ophtalmologiques spécialisés dans ce segment continue de s'accélérer.
- Par canal de distribution
En fonction du canal de distribution, le marché de la douleur oculaire est segmenté en appels d'offres directs, pharmacies hospitalières, pharmacies de détail, pharmacies en ligne, etc. Le segment des appels d'offres directs a représenté la plus grande part de chiffre d'affaires du marché en 2025, grâce aux achats massifs de médicaments et de thérapies contre la douleur oculaire par les hôpitaux publics et privés, via des contrats gouvernementaux et des accords d'approvisionnement institutionnels. Les appels d'offres directs garantissent une rentabilité optimale et une rationalisation des chaînes d'approvisionnement, en particulier dans les pays dotés de systèmes de santé centralisés. Ce segment est un canal privilégié pour les achats en gros de médicaments et de dispositifs ophtalmiques essentiels utilisés dans la prise en charge chirurgicale et chronique de la douleur.
Le segment des appels d'offres directs devrait connaître la croissance la plus rapide, soit 8,7 % entre 2025 et 2032, grâce à la préférence croissante des établissements de santé et des organismes gouvernementaux pour des modèles d'approvisionnement rentables. L'importance croissante accordée aux achats groupés, associée à des processus d'appel d'offres transparents, garantit une meilleure rentabilité et un meilleur accès à des produits médicaux de haute qualité. Alors que de plus en plus d'hôpitaux et d'organismes de santé publique adoptent des mécanismes d'appel d'offres directs pour rationaliser les chaînes d'approvisionnement et réduire les coûts intermédiaires, la demande pour ce segment continue de croître.
Analyse régionale du marché de la douleur oculaire
- L'Amérique du Nord devrait dominer le marché de la douleur oculaire, représentant 45,05 % du chiffre d'affaires total en 2025, en raison d'une forte prévalence de maladies oculaires chroniques telles que le glaucome, la sécheresse oculaire et les migraines oculaires, ainsi que d'une solide infrastructure de soins de santé et de l'adoption précoce de modalités de traitement avancées.
- La région bénéficie d’investissements importants en R&D, d’un accès généralisé aux soins ophtalmiques et d’une sensibilisation croissante au diagnostic précoce et à la santé oculaire – des facteurs qui soutiennent la croissance continue des solutions contre la douleur oculaire, sur ordonnance et en vente libre.
- Les grands pays comme les États-Unis et le Canada sont à l’avant-garde de l’innovation ophtalmique, avec des essais cliniques en expansion, une couverture d’assurance élevée et de solides pipelines pharmaceutiques favorisant la disponibilité de nouvelles thérapies de gestion de la douleur oculaire.
- La croissance de la population gériatrique, l'augmentation des dépenses de santé par habitant et la présence d'acteurs de premier plan sur le marché et d'organisations de santé oculaire contribuent davantage au rôle influent de l'Amérique du Nord sur le marché mondial de la douleur oculaire.
Aperçu du marché américain de la douleur oculaire
En 2025, le marché américain de la douleur oculaire représentait la plus grande part de chiffre d'affaires du marché nord-américain de la douleur oculaire, grâce à son infrastructure de soins de santé de pointe, à la forte prévalence des maladies oculaires chroniques telles que le glaucome, le syndrome de l'œil sec et les migraines oculaires, et à la forte présence de sociétés pharmaceutiques de premier plan. La croissance de la population gériatrique, la forte pénétration des assurances et la large disponibilité des médicaments sur ordonnance et des thérapies innovantes soutiennent la demande continue pour une prise en charge efficace de la douleur oculaire. L'innovation continue dans les systèmes d'administration de médicaments ophtalmiques et la sensibilisation croissante des patients stimulent l'expansion du marché.
Aperçu du marché canadien de la douleur oculaire
Le marché canadien de la douleur oculaire devrait enregistrer un TCAC important en Amérique du Nord de 2025 à 2032, stimulé par l'augmentation des investissements dans la santé oculaire, l'incidence croissante des troubles oculaires liés à l'âge et la sensibilisation croissante du public à l'intervention précoce contre la douleur oculaire. Le solide système de santé publique du pays favorise l'accès aux soins ophtalmologiques et aux traitements subventionnés, tandis que les programmes nationaux visant à réduire la perte de vision évitable créent des opportunités de croissance. L'adoption croissante de thérapies non invasives et d'outils de santé numériques pour les soins oculaires contribue également au rôle croissant du Canada sur le marché régional de la douleur oculaire.
Aperçu du marché européen de la douleur oculaire
Le marché européen de la douleur oculaire a représenté une part de marché substantielle en 2025, stimulé par la charge croissante des maladies oculaires chroniques et liées à l'âge, telles que le glaucome, l'uvéite et le syndrome de l'œil sec. La région bénéficie d'un accès universel aux soins de santé, d'une forte sensibilisation des patients et d'une adoption généralisée des solutions ophtalmiques sur ordonnance et en vente libre. Des cadres réglementaires favorables, une recherche clinique active et la présence d'entreprises ophtalmiques de premier plan continuent de soutenir la croissance du marché dans la région.
Aperçu du marché allemand de la douleur oculaire
En 2025, le marché allemand de la douleur oculaire détenait la plus grande part de chiffre d'affaires en Europe, grâce à son infrastructure de santé de pointe, à sa forte industrie pharmaceutique et à la croissance de sa population gériatrique. L'accent mis par le pays sur le diagnostic précoce et les soins oculaires spécialisés stimule une demande constante de traitements contre la douleur oculaire. Le soutien au remboursement et l'adoption massive de thérapies innovantes positionnent l'Allemagne comme un acteur clé du marché européen de la douleur oculaire.
Aperçu du marché britannique de la douleur oculaire
Le marché britannique des douleurs oculaires connaît une croissance constante, soutenue par une sensibilisation accrue à la santé oculaire, des taux plus élevés de fatigue oculaire numérique et des initiatives gouvernementales axées sur les soins ophtalmologiques préventifs. L'augmentation des problèmes de vision liés aux écrans et des douleurs oculaires liées aux migraines chez les jeunes contribue à une plus grande adoption des produits en vente libre et des solutions de soins oculaires axées sur le bien-être. Le renforcement du soutien du NHS aux services de santé oculaire et la présence de chaînes de pharmacies de détail améliorent l'accessibilité du marché.
Aperçu du marché de la douleur oculaire en Asie-Pacifique
En 2025, le marché de la douleur oculaire en Asie-Pacifique a conquis la plus grande part du marché mondial de la douleur oculaire, représentant 18,78 % du chiffre d'affaires total, et devrait connaître le taux de croissance annuel composé le plus élevé, soit 7,2 %. Cette croissance est portée par la vaste base agricole de la région, l'expansion de la culture d'algues et l'adoption croissante de pratiques durables. Les subventions gouvernementales, la sensibilisation croissante à l'environnement et la demande croissante de produits alimentaires biologiques accélèrent la transition vers des intrants biosourcés comme les engrais à base d'algues dans toute la région.
Aperçu du marché chinois de la douleur oculaire
En 2025, le marché chinois des douleurs oculaires a dominé le marché Asie-Pacifique, grâce à son littoral étendu, à sa forte capacité de culture d'algues et à ses infrastructures de transformation robustes. L'engagement du gouvernement chinois en faveur d'une agriculture durable, conjugué à une forte demande intérieure de produits sans produits chimiques, favorise l'adoption généralisée des engrais à base d'algues. Les investissements stratégiques dans les biotechnologies marines et la présence de grands fabricants renforcent encore le leadership de la Chine sur le marché régional.
Aperçu du marché indien de la douleur oculaire
Le marché indien des douleurs oculaires connaît une croissance significative, portée par une sensibilisation croissante à l'agriculture biologique, des programmes soutenus par le gouvernement tels que PM-PRANAM et Paramparagat Krishi Vikas Yojana, et une attention croissante portée à la restauration de la santé des sols. L'importante main-d'œuvre agricole du pays et le prix abordable des engrais à base d'algues favorisent leur adoption, notamment pour les cultures de céréales, de légumes et de légumineuses dans les régions côtières et intérieures.
Part de marché de la douleur oculaire
L’industrie de la douleur oculaire est principalement dirigée par des entreprises bien établies, notamment :
- Alcon Inc (Suisse)
- Allergène (Irlande)
- Bausch & Lomb (États-Unis)
- Novartis SA
- Kvenue (États-Unis)
- Pfizer Inc. (États-Unis)
- Merck Sharp & Dohme Corp, une filiale de Merck (États-Unis)
- Ocular Therapeutix (États-Unis)
- Sun Pharmaceutical (Inde)
- Eyepoint Pharmaceuticals (États-Unis)
- Fera Pharmaceuticals (États-Unis)
- IACTA Pharmaceutical (États-Unis)
- TheraLife®, Inc (États-Unis)
- Opticarma India SMC Pvt. Ltd. (Inde)
- Wellona Pharma (Inde)
- Oscar Remedies Pvt. Ltd (Inde)
- Opdenas Lifesciences (Inde)
- Choroid Laboratories Pvt. Ltd. (Inde)
- Sylentis (Espagne)
- Tarsier Pharma Ltd (Israël)
- Vyluma (États-Unis)
- Okyo Pharma Limited (Royaume-Uni)
- Alderya Therapeutics (États-Unis)
- Novaliq GMBH (Allemagne)
- Formosapharma Pharmaceutical Inc. (Taïwan)
- iVIEW Therapeutics, Inc. (États-Unis)
Derniers développements sur le marché mondial de la douleur oculaire
- En octobre 2020, Nevakar Inc. et Zhaoke Ophthalmology ont conclu un accord de licence exclusif pour le développement et la commercialisation de NVK002, un nouveau collyre pour la myopie pédiatrique, en Grande Chine, en Corée du Sud et en Asie du Sud-Est. Cet accord comprend jusqu'à 102 millions de dollars US de paiements d'étape et de redevances échelonnées, positionnant Zhaoke comme leader du traitement régional de la myopie grâce à ce traitement innovant en phase avancée.
- En janvier 2021, Nevakar Inc. et les Laboratoires Théa ont conclu un accord de licence exclusif pour la commercialisation de NVK002 en Europe et dans certaines régions d'Afrique du Nord. NVK002, un collyre expérimental destiné à ralentir la progression de la myopie chez l'enfant, est en phase III d'essais cliniques. Nevakar pourrait percevoir jusqu'à 135 millions de dollars de paiements d'étape, ainsi que des redevances échelonnées sur les ventes futures dans les régions sous licence.
- En juillet 2025, Bausch + Lomb a annoncé la publication des données cliniques de phase 3 pour les gouttes ophtalmiques LUMIFY sans conservateur, anti-rougeurs. Ce développement confirme l'engagement de l'entreprise en faveur de l'innovation dans les soins oculaires en vente libre. La formulation sans conservateur a démontré une réduction rapide et durable des rougeurs, avec un profil de sécurité favorable. Cette avancée élargit l'offre de produits de Bausch + Lomb pour le confort oculaire et positionne la marque fortement sur le segment des produits sans conservateur.
- En juillet 2025, Aldeyra Therapeutics a annoncé que sa nouvelle demande d'autorisation de mise sur le marché (NDA) pour le reproxalap dans le traitement de la sécheresse oculaire avait été acceptée par la Food and Drug Administration (FDA) américaine. Cette nouvelle demande reposait sur un seul essai clinique ayant atteint le critère d'évaluation principal, à savoir la réduction de l'inconfort oculaire, exigé par la FDA.
- En mai 2025, Bausch + Lomb a annoncé le lancement aux États-Unis des gouttes ophtalmiques anti-rougeurs Lumify sans conservateur, élargissant ainsi sa gamme populaire Lumify. Cette nouvelle formule soulage les rougeurs oculaires sans conservateur, répondant ainsi aux besoins des patients sensibles. Ce lancement renforce l'engagement de Bausch + Lomb en faveur de l'innovation en matière de santé oculaire et enrichit sa gamme de produits de soins oculaires sans ordonnance, ciblant le confort du consommateur et la protection à long terme de la surface oculaire.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL OCULAR PAIN MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 GLOBAL OCULAR PAIN MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.3 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.4 PATENT ANALYSIS-
4.5 SUPPLY CHAIN
4.6 VALUE CHAIN
5 TARIFF IMPACT ANALYSIS – GLOBAL OCULAR PAIN MARKET
5.1 IMPACT ON RAW MATERIAL AND API IMPORTS
5.2 FINISHED PRODUCT TARIFFS AND MARKET ACCESS
5.3 MEDICAL DEVICE COMPONENT TARIFFS
5.4 TRADE AGREEMENTS AND HARMONIZATION BENEFITS
5.5 STRATEGIC SHIFTS AND LOCALIZATION
6 GLOBAL OCULAR PAIN MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE
7.1.2 RISING PREVALENCE OF OPHTHALMIC DISORDERS AND OCULAR PAINS
7.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES
7.1.4 GROWING CASES OF OCULAR MIGRAINE
7.2 RESTRAINTS
7.2.1 SIDE EFFECTS OF EYE TREATMENT MEDICINES
7.2.2 HIGH COST OF EYE TREATMENT AND MEDICATION
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS AND TREATMENT
7.4 CHALLENGES
7.4.1 STRINGENT RULES & REGULATIONS
7.4.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT
8 GLOBAL OCULAR PAIN MARKET, BY DISEASE TYPE
8.1 OVERVIEW
8.2 OCULAR PAIN WITH EYE DISEASES
8.3 OCULAR PAIN WITHOUT PRIMARY EYE DISEASES
9 GLOBAL OCULAR PAIN MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIAGNOSIS
9.3 TREATMENT
10 GLOBAL OCULAR PAIN MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 GLAUCOMA
10.3 BLEPHARITIS
10.4 CONJUNCTIVITIS
10.5 CORNEAL ABRASION
10.6 STY
10.7 IRITIS
10.8 SINUSITIS
10.9 MIGRAINES
10.1 OTHERS
11 GLOBAL OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 TOPICAL
11.3 INTRAOCULAR
11.4 PERIOCULAR
11.5 ORAL
11.6 OTHERS
12 GLOBAL OCULAR PAIN MARKET, BY POPULATION TYPE
12.1 OVERVIEW
12.2 ADULT
12.3 GERIATRIC
13 GLOBAL OCULAR PAIN MARKET, BY DRUG TYPE
13.1 OVERVIEW
13.2 PRESCRIPTION
13.3 OVER THE COUNTER
14 GLOBAL OCULAR PAIN MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALITY CLINICS
14.4 HOME HEALTHCARE
14.5 OCULAR PAIN CENTERS
14.6 AMBULATORY SURGICAL CENTERS
14.7 OTHERS
15 GLOBAL OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACY
15.4 RETAIL PHARMACY
15.5 ONLINE PHARMACY
15.6 OTHERS
16 GLOBAL OCULAR PAIN MARKET, BY REGION
16.1 OVERVIEW
16.2 NORTH AMERICA
16.2.1 U.S.
16.2.2 CANADA
16.2.3 MEXICO
16.3 EUROPE
16.3.1 GERMANY
16.3.2 ITALY
16.3.3 FRANCE
16.3.4 U.K.
16.3.5 SPAIN
16.3.6 NETHERLANDS
16.3.7 RUSSIA
16.3.8 SWITZERLAND
16.3.9 TURKEY
16.3.10 AUSTRIA
16.3.11 NORWAY
16.3.12 HUNGARY
16.3.13 LITHUANIA
16.3.14 IRELAND
16.3.15 POLAND
16.3.16 REST OF EUROPE
16.4 ASIA PACIFIC
16.4.1 JAPAN
16.4.2 CHINA
16.4.3 INDIA
16.4.4 SOUTH KOREA
16.4.5 AUSTRALIA
16.4.6 SINGAPORE
16.4.7 THAILAND
16.4.8 MALAYSIA
16.4.9 INDONESIA
16.4.10 PHILIPPINES
16.4.11 VIETNAM
16.4.12 REST OF ASIA-PACIFIC
16.5 SOUTH AMERICA
16.5.1 BRAZIL
16.5.2 ARGENTINA
16.5.3 PERU
16.5.4 REST OF SOUTH AMERICA
16.6 MIDDLE EAST AND AFRICA
16.6.1 SOUTH AFRICA
16.6.2 SAUDI ARABIA
16.6.3 U.A.E.
16.6.4 EGYPT
16.6.5 KUWAIT
16.6.6 ISRAEL
16.6.7 REST OF MIDDLE EAST AND AFRICA
17 GLOBAL OCULAR PAIN MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILES
19.1 ALCON INC
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 ALLERGAN (AN ABBVIE COMPANY)
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 BAUSCH + LOMB
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 KENVUE
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 PFIZER INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 ALDEYRA THERAPEUTICS, INC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT/NEWS
19.7 CHOROID LABORATORIES
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 EYEPOINT PHARMACEUTICALS, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 FERA PHARMACEUTICALS
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 FORMOSAPHARMA PHARMACEUTICAL INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT NEWS
19.11 IACTA PHARMACEUTICALS
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 IVIEW THERAPEUTICS, INC..
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 MERCK & CO., INC., A SUBSIDIARY OF MERCK
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 NOVALIQ GMBH
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 OCULAR THERAPEUTIX, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS/NEWS
19.16 OKYO PHARMA, LIMITED
19.16.1 COMPANY SNAPSHOT
19.16.2 1.1.4 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS/NEWS
19.17 OPDENAS LIFESCIENCES.
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 OPTICARMA INDIA SMC PRIVATE LIMITED
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENTS/NEWS
19.19 OSCAR REMEDIES PVT. LTD.
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS/NEWS
19.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
19.21 SYLENTIS
19.21.1 COMPANY SNAPSHOT
19.21.2 PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENT
19.22 TARSIER PHARMA LTD.
19.22.1 COMPANY SNAPSHOT
19.22.2 PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENT
19.23 THERALIFE, INC.
19.23.1 COMPANY SNAPSHOT
19.23.2 PRODUCT PORTFOLIO
19.23.3 RECENT DEVELOPMENT
19.24 VYLUMA
19.24.1 COMPANY SNAPSHOT
19.24.2 PIPELINE PORTFOLIO
19.24.3 RECENT DEVELOPMENT
19.25 WELLONA PHARMA
19.25.1 COMPANY SNAPSHOT
19.25.2 PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENTS/NEWS
20 QUESTIONNAIRE
21 RELATED REPORTS
Liste des tableaux
TABLE 1 GLOBAL OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 GLOBAL OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 GLOBAL OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY TYPE OF DISEASE, 2018-2032 (USD THOUSAND)
TABLE 4 GLOBAL OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 GLOBAL OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 GLOBAL OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 GLOBAL DIAGNOSIS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 8 GLOBAL DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 GLOBAL SENSORY TESTING IN OCULAR PAIN IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 10 GLOBAL IMAGING TEST IN OCULAR PAIN IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 GLOBAL TREATMENT IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 GLOBAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 GLOBAL LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 GLOBAL TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 GLOBAL STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 17 GLOBAL OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 18 GLOBAL GLAUCOMA IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 GLOBAL BLEPHARITIS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 GLOBAL CONJUNCTIVITIS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 21 GLOBAL CORNEAL ABRASION IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 GLOBAL STY IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 GLOBAL IRITIS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 GLOBAL SINUSITIS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 GLOBAL MIGRAINES IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 GLOBAL OTHERS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 GLOBAL OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 28 GLOBAL TOPICAL IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 GLOBAL TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 30 GLOBAL INTRAOCULAR IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 GLOBAL INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 32 GLOBAL PERIOCULAR IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 GLOBAL PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 34 GLOBAL ORAL IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 GLOBAL ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 36 GLOBAL OTHERS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 37 GLOBAL OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 38 GLOBAL ADULT IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 GLOBAL GERIATRIC IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 GLOBAL OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 GLOBAL PRESCRIPTION IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 42 GLOBAL OVER THE COUNTER (OTC) IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 43 GLOBAL OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 44 GLOBAL HOSPITALS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 GLOBAL SPECIALTY CLINICS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 46 GLOBAL HOME HEALTHCARE IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 GLOBAL OCULAR PAIN CENTERS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 48 GLOBAL AMBULATORY SURGICAL CENTERS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 49 GLOBAL OTHERS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 50 GLOBAL OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 51 GLOBAL DIRECT TENDER IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 52 GLOBAL HOSPITAL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 53 GLOBAL RETAIL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 54 GLOBAL ONLINE PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 55 GLOBAL OTHERS IN OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 56 GLOBAL OCULAR PAIN MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 57 NORTH AMERICA OCULAR PAIN MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 58 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 59 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 NORTH AMERICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 NORTH AMERICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 NORTH AMERICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 NORTH AMERICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 NORTH AMERICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 71 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 72 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 73 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 74 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 75 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 76 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 NORTH AMERICA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 79 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 80 U.S. OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 U.S. OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 U.S. OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 U.S. OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 U.S. DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 U.S. SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 U.S. IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 U.S. TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 U.S. LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 89 U.S. TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 U.S. NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 U.S. STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 U.S. OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 93 U.S. OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 94 U.S. TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 95 U.S. INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 96 U.S. PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 97 U.S. ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 98 U.S. OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 U.S. OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 U.S. OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 101 U.S. OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 102 CANADA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 CANADA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 CANADA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 CANADA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 CANADA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 CANADA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 CANADA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 CANADA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 CANADA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 CANADA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 CANADA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 CANADA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 CANADA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 115 CANADA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 116 CANADA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 117 CANADA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 118 CANADA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 119 CANADA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 120 CANADA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 CANADA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 CANADA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 123 CANADA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 124 MEXICO OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 MEXICO OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 MEXICO OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 MEXICO OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 MEXICO DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 MEXICO SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 MEXICO IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 131 MEXICO TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 MEXICO LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 MEXICO TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 MEXICO STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 MEXICO OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 137 MEXICO OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 138 MEXICO TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 139 MEXICO INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 140 MEXICO PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 141 MEXICO ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 142 MEXICO OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 MEXICO OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 MEXICO OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 145 MEXICO OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 146 EUROPE OCULAR PAIN MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 147 EUROPE OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 EUROPE OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 EUROPE OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 EUROPE OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 EUROPE DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 EUROPE SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 EUROPE IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 EUROPE TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 EUROPE LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 156 EUROPE TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 EUROPE STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 EUROPE OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 160 EUROPE OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 161 EUROPE TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 162 EUROPE INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 163 EUROPE PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 164 EUROPE ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 165 EUROPE OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 EUROPE OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 EUROPE OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 168 EUROPE OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 169 GERMANY OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 GERMANY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 GERMANY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 172 GERMANY OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 173 GERMANY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 174 GERMANY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 GERMANY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 GERMANY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 GERMANY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 GERMANY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 180 GERMANY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 GERMANY OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 182 GERMANY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 183 GERMANY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 184 GERMANY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 185 GERMANY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 186 GERMANY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 187 GERMANY OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 188 GERMANY OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 GERMANY OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 190 GERMANY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 191 ITALY OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 ITALY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 ITALY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 ITALY OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 ITALY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 ITALY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 ITALY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 ITALY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 ITALY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 ITALY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 ITALY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 ITALY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 ITALY OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 204 ITALY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 205 ITALY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 206 ITALY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 207 ITALY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 208 ITALY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 209 ITALY OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 ITALY OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 ITALY OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 212 ITALY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 213 FRANCE OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 FRANCE OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 FRANCE OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 FRANCE OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 FRANCE DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 FRANCE SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 FRANCE IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 FRANCE TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 FRANCE LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 FRANCE TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 224 FRANCE STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 FRANCE OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 226 FRANCE OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 227 FRANCE TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 228 FRANCE INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 229 FRANCE PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 230 FRANCE ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 231 FRANCE OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 FRANCE OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 FRANCE OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 234 FRANCE OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 235 U.K. OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 236 U.K. OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 U.K. OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 U.K. OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 239 U.K. DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 U.K. SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 241 U.K. IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 242 U.K. TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 U.K. LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 244 U.K. TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 245 U.K. NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 U.K. STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 U.K. OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 248 U.K. OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 249 U.K. TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 250 U.K. INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 251 U.K. PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 252 U.K. ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 253 U.K. OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 U.K. OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 U.K. OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 256 U.K. OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 257 SPAIN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 SPAIN OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 SPAIN OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 SPAIN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 SPAIN DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 SPAIN SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 263 SPAIN IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 264 SPAIN TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 SPAIN LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 SPAIN TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 SPAIN STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 SPAIN OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 270 SPAIN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 271 SPAIN TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 272 SPAIN INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 273 SPAIN PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 274 SPAIN ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 275 SPAIN OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 SPAIN OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 SPAIN OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 278 SPAIN OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 279 NETHERLANDS OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 280 NETHERLANDS OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 281 NETHERLANDS OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 NETHERLANDS OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 NETHERLANDS DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 284 NETHERLANDS SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 NETHERLANDS IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 286 NETHERLANDS TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 NETHERLANDS LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 288 NETHERLANDS TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 289 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 NETHERLANDS STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 291 NETHERLANDS OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 292 NETHERLANDS OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 293 NETHERLANDS TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 294 NETHERLANDS INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 295 NETHERLANDS PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 296 NETHERLANDS ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 297 NETHERLANDS OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 NETHERLANDS OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 NETHERLANDS OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 300 NETHERLANDS OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 301 RUSSIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 RUSSIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 303 RUSSIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 RUSSIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 RUSSIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 RUSSIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 RUSSIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 308 RUSSIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 309 RUSSIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 310 RUSSIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 312 RUSSIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 313 RUSSIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 314 RUSSIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 315 RUSSIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 316 RUSSIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 317 RUSSIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 318 RUSSIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 319 RUSSIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 RUSSIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 321 RUSSIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 322 RUSSIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 323 SWITZERLAND OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 SWITZERLAND OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 SWITZERLAND OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 SWITZERLAND OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 SWITZERLAND DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 328 SWITZERLAND SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 329 SWITZERLAND IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 330 SWITZERLAND TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 SWITZERLAND LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 SWITZERLAND TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 333 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 334 SWITZERLAND STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 335 SWITZERLAND OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 336 SWITZERLAND OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 337 SWITZERLAND TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 338 SWITZERLAND INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 339 SWITZERLAND PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 340 SWITZERLAND ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 341 SWITZERLAND OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 342 SWITZERLAND OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 343 SWITZERLAND OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 344 SWITZERLAND OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 345 TURKEY OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 TURKEY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 347 TURKEY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 348 TURKEY OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 349 TURKEY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 TURKEY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 TURKEY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 TURKEY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 353 TURKEY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 TURKEY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 TURKEY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 TURKEY OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 358 TURKEY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 359 TURKEY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 360 TURKEY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 361 TURKEY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 362 TURKEY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 363 TURKEY OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 364 TURKEY OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 365 TURKEY OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 366 TURKEY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 367 AUSTRIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 368 AUSTRIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 369 AUSTRIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 AUSTRIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 371 AUSTRIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 AUSTRIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 373 AUSTRIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 374 AUSTRIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 375 AUSTRIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 376 AUSTRIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 377 AUSTRIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 378 AUSTRIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 AUSTRIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 380 AUSTRIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 381 AUSTRIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 382 AUSTRIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 383 AUSTRIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 384 AUSTRIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 385 AUSTRIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 386 AUSTRIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 AUSTRIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 388 AUSTRIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 389 NORWAY OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 NORWAY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 391 NORWAY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 392 NORWAY OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 NORWAY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 394 NORWAY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 395 NORWAY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 NORWAY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 397 NORWAY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 398 NORWAY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 399 NORWAY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 400 NORWAY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 NORWAY OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 402 NORWAY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 403 NORWAY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 404 NORWAY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 405 NORWAY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 406 NORWAY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 407 NORWAY OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 NORWAY OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 NORWAY OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 410 NORWAY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 411 HUNGARY OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 HUNGARY OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 413 HUNGARY OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 414 HUNGARY OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 HUNGARY DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 HUNGARY SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 HUNGARY IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 418 HUNGARY TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 419 HUNGARY LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 420 HUNGARY TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 421 HUNGARY NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 HUNGARY STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 423 HUNGARY OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 424 HUNGARY OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 425 HUNGARY TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 426 HUNGARY INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 427 HUNGARY PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 428 HUNGARY ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 429 HUNGARY OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 430 HUNGARY OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 431 HUNGARY OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 432 HUNGARY OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 433 LITHUANIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 434 LITHUANIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 435 LITHUANIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 436 LITHUANIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 LITHUANIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 438 LITHUANIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 439 LITHUANIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 LITHUANIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 441 LITHUANIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 442 LITHUANIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 LITHUANIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 444 LITHUANIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 445 LITHUANIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 446 LITHUANIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 447 LITHUANIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 448 LITHUANIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 449 LITHUANIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 450 LITHUANIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 451 LITHUANIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 LITHUANIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 453 LITHUANIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 454 LITHUANIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 455 IRELAND OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 IRELAND OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 IRELAND OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 458 IRELAND OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 IRELAND DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 460 IRELAND SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 461 IRELAND IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 462 IRELAND TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 463 IRELAND LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 464 IRELAND TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 465 IRELAND NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 466 IRELAND STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 467 IRELAND OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 468 IRELAND OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 469 IRELAND TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 470 IRELAND INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 471 IRELAND PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 472 IRELAND ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 473 IRELAND OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 474 IRELAND OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 475 IRELAND OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 476 IRELAND OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 477 POLAND OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 478 POLAND OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 479 POLAND OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 480 POLAND OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 481 POLAND DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 POLAND SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 483 POLAND IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 484 POLAND TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 485 POLAND LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 486 POLAND TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 POLAND NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 488 POLAND STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 489 POLAND OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 490 POLAND OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 491 POLAND TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 492 POLAND INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 493 POLAND PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 494 POLAND ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 495 POLAND OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 496 POLAND OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 497 POLAND OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 498 POLAND OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 499 REST OF EUROPE OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 500 ASIA-PACIFIC OCULAR PAIN MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 501 ASIA-PACIFIC OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 ASIA-PACIFIC OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 503 ASIA-PACIFIC OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 ASIA-PACIFIC OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 505 ASIA-PACIFIC DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 506 ASIA-PACIFIC SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 507 ASIA-PACIFIC IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 ASIA-PACIFIC TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 ASIA-PACIFIC LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 510 ASIA-PACIFIC TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 511 ASIA-PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 512 ASIA-PACIFIC STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 513 ASIA-PACIFIC OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 514 ASIA-PACIFIC OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 515 ASIA-PACIFIC TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 516 ASIA-PACIFIC INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 517 ASIA-PACIFIC PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 518 ASIA-PACIFIC ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 519 ASIA-PACIFIC OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 520 ASIA-PACIFIC OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 521 ASIA-PACIFIC OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 522 ASIA-PACIFIC OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 523 JAPAN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 524 JAPAN OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 525 JAPAN OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 526 JAPAN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 527 JAPAN DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 528 JAPAN SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 529 JAPAN IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 530 JAPAN TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 531 JAPAN LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 532 JAPAN TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 533 JAPAN NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 534 JAPAN STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 JAPAN OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 536 JAPAN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 537 JAPAN TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 538 JAPAN INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 539 JAPAN PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 540 JAPAN ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 541 JAPAN OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 542 JAPAN OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 543 JAPAN OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 544 JAPAN OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 545 CHINA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 546 CHINA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 547 CHINA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 548 CHINA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 549 CHINA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 550 CHINA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 551 CHINA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 552 CHINA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 553 CHINA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 554 CHINA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 555 CHINA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 556 CHINA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 557 CHINA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 558 CHINA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 559 CHINA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 560 CHINA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 561 CHINA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 562 CHINA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 563 CHINA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 564 CHINA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 565 CHINA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 566 CHINA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 567 INDIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 568 INDIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 569 INDIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 570 INDIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 571 INDIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 572 INDIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 573 INDIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 574 INDIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 575 INDIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 576 INDIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 577 INDIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 578 INDIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 579 INDIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 580 INDIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 581 INDIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 582 INDIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 583 INDIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 584 INDIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 585 INDIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 586 INDIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 587 INDIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 588 INDIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 589 SOUTH KOREA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 590 SOUTH KOREA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 591 SOUTH KOREA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 592 SOUTH KOREA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 593 SOUTH KOREA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 594 SOUTH KOREA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 595 SOUTH KOREA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 596 SOUTH KOREA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 597 SOUTH KOREA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 598 SOUTH KOREA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 599 SOUTH KOREA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 600 SOUTH KOREA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 601 SOUTH KOREA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 602 SOUTH KOREA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 603 SOUTH KOREA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 604 SOUTH KOREA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 605 SOUTH KOREA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 606 SOUTH KOREA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 607 SOUTH KOREA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 608 SOUTH KOREA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 609 SOUTH KOREA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 610 SOUTH KOREA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 611 AUSTRALIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 AUSTRALIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 613 AUSTRALIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 614 AUSTRALIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 615 AUSTRALIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 616 AUSTRALIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 617 AUSTRALIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 618 AUSTRALIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 619 AUSTRALIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 620 AUSTRALIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 621 AUSTRALIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 622 AUSTRALIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 623 AUSTRALIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 624 AUSTRALIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 625 AUSTRALIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 626 AUSTRALIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 627 AUSTRALIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 628 AUSTRALIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 629 AUSTRALIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 630 AUSTRALIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 631 AUSTRALIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 632 AUSTRALIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 633 SINGAPORE OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 634 SINGAPORE OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 635 SINGAPORE OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 636 SINGAPORE OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 637 SINGAPORE DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 638 SINGAPORE SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 639 SINGAPORE IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 640 SINGAPORE TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 641 SINGAPORE LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 642 SINGAPORE TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 643 SINGAPORE NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 644 SINGAPORE STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 645 SINGAPORE OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 646 SINGAPORE OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 647 SINGAPORE TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 648 SINGAPORE INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 649 SINGAPORE PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 650 SINGAPORE ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 651 SINGAPORE OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 652 SINGAPORE OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 653 SINGAPORE OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 654 SINGAPORE OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 655 THAILAND OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 656 THAILAND OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 657 THAILAND OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 658 THAILAND OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 659 THAILAND DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 660 THAILAND SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 661 THAILAND IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 662 THAILAND TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 663 THAILAND LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 664 THAILAND TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 665 THAILAND NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 666 THAILAND STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 667 THAILAND OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 668 THAILAND OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 669 THAILAND TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 670 THAILAND INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 671 THAILAND PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 672 THAILAND ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 673 THAILAND OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 674 THAILAND OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 675 THAILAND OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 676 THAILAND OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 677 MALAYSIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 678 MALAYSIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 679 MALAYSIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 680 MALAYSIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 681 MALAYSIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 682 MALAYSIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 683 MALAYSIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 684 MALAYSIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 685 MALAYSIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 686 MALAYSIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 687 MALAYSIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 688 MALAYSIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 689 MALAYSIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 690 MALAYSIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 691 MALAYSIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 692 MALAYSIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 693 MALAYSIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 694 MALAYSIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 695 MALAYSIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 696 MALAYSIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 697 MALAYSIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 698 MALAYSIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 699 INDONESIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 700 INDONESIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 701 INDONESIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 702 INDONESIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 703 INDONESIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 704 INDONESIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 705 INDONESIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 706 INDONESIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 707 INDONESIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 708 INDONESIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 709 INDONESIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 710 INDONESIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 711 INDONESIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 712 INDONESIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 713 INDONESIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 714 INDONESIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 715 INDONESIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 716 INDONESIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 717 INDONESIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 718 INDONESIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 719 INDONESIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 720 INDONESIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 721 PHILIPPINES OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 722 PHILIPPINES OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 723 PHILIPPINES OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 724 PHILIPPINES OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 725 PHILIPPINES DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 726 PHILIPPINES SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 727 PHILIPPINES IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 728 PHILIPPINES TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 729 PHILIPPINES LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 730 PHILIPPINES TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 731 PHILIPPINES NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 732 PHILIPPINES STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 733 PHILIPPINES OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 734 PHILIPPINES OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 735 PHILIPPINES TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 736 PHILIPPINES INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 737 PHILIPPINES PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 738 PHILIPPINES ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 739 PHILIPPINES OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 740 PHILIPPINES OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 741 PHILIPPINES OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 742 PHILIPPINES OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 743 VIETNAM OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 744 VIETNAM OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 745 VIETNAM OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 746 VIETNAM OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 747 VIETNAM DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 748 VIETNAM SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 749 VIETNAM IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 750 VIETNAM TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 751 VIETNAM LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 752 VIETNAM TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 753 VIETNAM NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 754 VIETNAM STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 755 VIETNAM OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 756 VIETNAM OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 757 VIETNAM TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 758 VIETNAM INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 759 VIETNAM PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 760 VIETNAM ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 761 VIETNAM OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 762 VIETNAM OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 763 VIETNAM OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 764 VIETNAM OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 765 REST OF ASIA-PACIFIC OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 766 SOUTH AMERICA OCULAR PAIN MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 767 SOUTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 768 SOUTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 769 SOUTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 770 SOUTH AMERICA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 771 SOUTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 772 SOUTH AMERICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 773 SOUTH AMERICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 774 SOUTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 775 SOUTH AMERICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 776 SOUTH AMERICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 777 SOUTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 778 SOUTH AMERICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 779 SOUTH AMERICA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 780 SOUTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 781 SOUTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 782 SOUTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 783 SOUTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 784 SOUTH AMERICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 785 SOUTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 786 SOUTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 787 SOUTH AMERICA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 788 SOUTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 789 BRAZIL OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 790 BRAZIL OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 791 BRAZIL OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 792 BRAZIL OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 793 BRAZIL DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 794 BRAZIL SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 795 BRAZIL IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 796 BRAZIL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 797 BRAZIL LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 798 BRAZIL TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 799 BRAZIL NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 800 BRAZIL STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 801 BRAZIL OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 802 BRAZIL OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 803 BRAZIL TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 804 BRAZIL INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 805 BRAZIL PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 806 BRAZIL ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 807 BRAZIL OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 808 BRAZIL OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 809 BRAZIL OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 810 BRAZIL OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 811 ARGENTINA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 812 ARGENTINA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 813 ARGENTINA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 814 ARGENTINA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 815 ARGENTINA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 816 ARGENTINA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 817 ARGENTINA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 818 ARGENTINA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 819 ARGENTINA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 820 ARGENTINA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 821 ARGENTINA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 822 ARGENTINA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 823 ARGENTINA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 824 ARGENTINA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 825 ARGENTINA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 826 ARGENTINA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 827 ARGENTINA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 828 ARGENTINA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 829 ARGENTINA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 830 ARGENTINA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 831 ARGENTINA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 832 ARGENTINA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 833 PERU OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 834 PERU OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 835 PERU OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 836 PERU OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 837 PERU DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 838 PERU SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 839 PERU IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 840 PERU TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 841 PERU LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 842 PERU TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 843 PERU NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 844 PERU STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 845 PERU OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 846 PERU OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 847 PERU TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 848 PERU INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 849 PERU PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 850 PERU ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 851 PERU OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 852 PERU OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 853 PERU OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 854 PERU OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 855 REST OF SOUTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 856 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 857 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 858 MIDDLE EAST AND AFRICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 859 MIDDLE EAST AND AFRICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 860 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 861 MIDDLE EAST AND AFRICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 862 MIDDLE EAST AND AFRICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 863 MIDDLE EAST AND AFRICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 864 MIDDLE EAST AND AFRICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 865 MIDDLE EAST AND AFRICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 866 MIDDLE EAST AND AFRICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 867 MIDDLE EAST AND AFRICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 868 MIDDLE EAST AND AFRICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 869 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 870 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 871 MIDDLE EAST AND AFRICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 872 MIDDLE EAST AND AFRICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 873 MIDDLE EAST AND AFRICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 874 MIDDLE EAST AND AFRICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 875 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 876 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 877 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 878 MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 879 SOUTH AFRICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 880 SOUTH AFRICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 881 SOUTH AFRICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 882 SOUTH AFRICA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 883 SOUTH AFRICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 884 SOUTH AFRICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 885 SOUTH AFRICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 886 SOUTH AFRICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 887 SOUTH AFRICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 888 SOUTH AFRICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 889 SOUTH AFRICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 890 SOUTH AFRICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 891 SOUTH AFRICA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 892 SOUTH AFRICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 893 SOUTH AFRICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 894 SOUTH AFRICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 895 SOUTH AFRICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 896 SOUTH AFRICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 897 SOUTH AFRICA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 898 SOUTH AFRICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 899 SOUTH AFRICA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 900 SOUTH AFRICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 901 SAUDI ARABIA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 902 SAUDI ARABIA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 903 SAUDI ARABIA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 904 SAUDI ARABIA OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 905 SAUDI ARABIA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 906 SAUDI ARABIA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 907 SAUDI ARABIA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 908 SAUDI ARABIA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 909 SAUDI ARABIA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 910 SAUDI ARABIA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 911 SAUDI ARABIA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 912 SAUDI ARABIA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 913 SAUDI ARABIA OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 914 SAUDI ARABIA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 915 SAUDI ARABIA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 916 SAUDI ARABIA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 917 SAUDI ARABIA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 918 SAUDI ARABIA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 919 SAUDI ARABIA OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 920 SAUDI ARABIA OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 921 SAUDI ARABIA OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 922 SAUDI ARABIA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 923 U.A.E. OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 924 U.A.E. OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 925 U.A.E. OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 926 U.A.E. OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 927 U.A.E. DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 928 U.A.E. SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 929 U.A.E. IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 930 U.A.E. TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 931 U.A.E. LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 932 U.A.E. TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 933 U.A.E. NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 934 U.A.E. STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 935 U.A.E. OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 936 U.A.E. OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 937 U.A.E. TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 938 U.A.E. INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 939 U.A.E. PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 940 U.A.E. ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 941 U.A.E. OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 942 U.A.E. OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 943 U.A.E. OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 944 U.A.E. OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 945 EGYPT OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 946 EGYPT OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 947 EGYPT OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 948 EGYPT OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 949 EGYPT DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 950 EGYPT SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 951 EGYPT IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 952 EGYPT TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 953 EGYPT LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 954 EGYPT TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 955 EGYPT NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 956 EGYPT STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 957 EGYPT OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 958 EGYPT OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 959 EGYPT TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 960 EGYPT INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 961 EGYPT PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 962 EGYPT ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 963 EGYPT OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 964 EGYPT OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 965 EGYPT OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 966 EGYPT OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 967 KUWAIT OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 968 KUWAIT OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 969 KUWAIT OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 970 KUWAIT OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 971 KUWAIT DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 972 KUWAIT SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 973 KUWAIT IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 974 KUWAIT TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 975 KUWAIT LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 976 KUWAIT TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 977 KUWAIT NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 978 KUWAIT STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 979 KUWAIT OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 980 KUWAIT OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 981 KUWAIT TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 982 KUWAIT INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 983 KUWAIT PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 984 KUWAIT ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 985 KUWAIT OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 986 KUWAIT OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 987 KUWAIT OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 988 KUWAIT OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 989 ISRAEL OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 990 ISRAEL OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 991 ISRAEL OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
TABLE 992 ISRAEL OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 993 ISRAEL DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 994 ISRAEL SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 995 ISRAEL IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 996 ISRAEL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 997 ISRAEL LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 998 ISRAEL TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 999 ISRAEL NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1000 ISRAEL STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1001 ISRAEL OCULAR PAIN MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 1002 ISRAEL OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1003 ISRAEL TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1004 ISRAEL INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1005 ISRAEL PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION 2018-2032 (USD THOUSAND)
TABLE 1006 ISRAEL ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1007 ISRAEL OCULAR PAIN MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 1008 ISRAEL OCULAR PAIN MARKET, BY POPULATION TYPE, 2018-2032 (USD THOUSAND)
TABLE 1009 ISRAEL OCULAR PAIN MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1010 ISRAEL OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1011 REST OF MIDDLE EAST AND AFRICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2018-2032 (USD THOUSAND)
Liste des figures
FIGURE 1 GLOBAL OCULAR PAIN MARKET: SEGMENTATION
FIGURE 2 GLOBAL OCULAR PAIN MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL OCULAR PAIN MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL OCULAR PAIN MARKET: GLOBAL VS REGIONAL ANALYSIS
FIGURE 5 GLOBAL OCULAR PAIN MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL OCULAR PAIN MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL OCULAR PAIN MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL OCULAR PAIN MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 GLOBAL OCULAR PAIN MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 GLOBAL OCULAR PAIN MARKET: SEGMENTATION
FIGURE 11 GLOBAL OCULAR PAIN MARKET: EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL OCULAR PAIN MARKET, AND IS PROJECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE IS EXPECTED TO DRIVE THE GLOBAL OCULAR PAIN MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 15 OCULAR PAIN WITH EYE DISEASE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL OCULAR PAIN MARKET IN 2025 AND 2032
FIGURE 16 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR OCULAR PAIN MANUFACTURERS IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 17 COUNTRY V/S NUMBER OF PATENTS
FIGURE 18 KEY APPLICANTS V/S NUMBER OF PATENTS.
FIGURE 19 INTERNATIONAL PATENT CLASSIFICATION V/S NUMBER OF PATENTS
FIGURE 20 NUMBER OF PATENT PUBLICATIONS PER YEAR.
FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL OCULAR PAIN MARKET
FIGURE 22 GLOBAL OCULAR PAIN MARKET: BY DISEASE TYPE, 2024
FIGURE 23 GLOBAL OCULAR PAIN MARKET: BY DISEASE TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 24 GLOBAL OCULAR PAIN MARKET: BY DISEASE TYPE, CAGR (2025- 2032)
FIGURE 25 GLOBAL OCULAR PAIN MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 26 GLOBAL OCULAR PAIN MARKET: BY TYPE, 2024
FIGURE 27 GLOBAL OCULAR PAIN MARKET: BY TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 28 GLOBAL OCULAR PAIN MARKET: BY TYPE, CAGR (2025- 2032)
FIGURE 29 GLOBAL OCULAR PAIN MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 GLOBAL OCULAR PAIN MARKET: BY APPLICATION, 2024
FIGURE 31 GLOBAL OCULAR PAIN MARKET: BY APPLICATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 32 GLOBAL OCULAR PAIN MARKET: BY APPLICATION, CAGR (2025- 2032)
FIGURE 33 GLOBAL OCULAR PAIN MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 34 GLOBAL OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2024
FIGURE 35 GLOBAL OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 36 GLOBAL OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025- 2032)
FIGURE 37 GLOBAL OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 38 GLOBAL OCULAR PAIN MARKET: BY POPULATION TYPE, 2024
FIGURE 39 GLOBAL OCULAR PAIN MARKET: BY POPULATION TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 40 GLOBAL OCULAR PAIN MARKET: BY POPULATION TYPE, CAGR (2025- 2032)
FIGURE 41 GLOBAL OCULAR PAIN MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 42 GLOBAL OCULAR PAIN MARKET: BY DRUG TYPE, 2024
FIGURE 43 GLOBAL OCULAR PAIN MARKET: BY DRUG TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 44 GLOBAL OCULAR PAIN MARKET: BY DRUG TYPE, CAGR (2025- 2032)
FIGURE 45 GLOBAL OCULAR PAIN MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 46 GLOBAL OCULAR PAIN MARKET: BY END USER, 2024
FIGURE 47 GLOBAL OCULAR PAIN MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 48 GLOBAL OCULAR PAIN MARKET: BY END USER, CAGR (2025- 2032)
FIGURE 49 GLOBAL OCULAR PAIN MARKET: BY END USER, LIFELINE CURVE
FIGURE 50 GLOBAL OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 51 GLOBAL OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 52 GLOBAL OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)
FIGURE 53 GLOBAL OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 54 GLOBAL OCULAR PAIN MARKET: SNAPSHOT (2024)
FIGURE 55 GLOBAL OCULAR PAIN MARKET: COMPANY SHARE 2024 (%)
FIGURE 56 NORTH AMERICA OCULAR PAIN MARKET: COMPANY SHARE 2024 (%)
FIGURE 57 EUROPE OCULAR PAIN MARKET: COMPANY SHARE 2024 (%)
FIGURE 58 ASIA-PACIFIC OCULAR PAIN MARKET: COMPANY SHARE 2024 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
